Need help finding what you are looking for?
Contact Us
PUBLISHER: BIS Research Inc. | PRODUCT CODE: 1213637
PUBLISHER: BIS Research Inc. | PRODUCT CODE: 1213637
Targeted Sequencing Market - A Global and Regional Analysis: Focus on Product Type, Target Enrichment Method, Type of Target Capture, Application, End User, and Region Analysis - Analysis and Forecast, 2022-2032
PUBLISHED:
PAGES: 256 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
“Global Targeted Sequencing Market to Reach $10,976.1 Million by 2032.”
Industry Overview
The global targeted sequencing market is projected to reach $10,976.1 million by 2032 from $3,198.8 million in 2022, growing at a CAGR of 13.12% during the forecast period 2022-2032. The growth in the global targeted sequencing market is expected to be driven by the increased use of targeted sequencing in clinical laboratories and diagnostic applications, especially in cancer research.
Market Lifecycle Stage
Targeted sequencing is a cost-effective and rapid way to detect novel and known variants in selected genetic or genomic regions. There are several different methods of DNA/RNA sequencing depending on the scale of the region being sequenced. Next-generation sequencing (NGS) is the most used method for targeted sequencing, which offers good scalability, speed, and resolution to evaluate the targeted regions of interest. Other methods include sanger sequencing and CRISPR.
The major advantage of targeted sequencing as compared to whole genome sequencing is the smaller and more manageable data sets created, which are significantly easier to analyze. Targeted next-generation sequencing focuses on specific genomic areas of interest, which is ideal for examining specific pathways or targeted resequencing. Furthermore, it is more rapid and cost-effective as compared to whole genome sequencing and allows deeper sequencing. This is a powerful and especially sensitive method of identifying gene mutations and variants, including rare variants.
Impact
- The presence of major kits/panels and assay providers of targeted sequencing has a major impact on the market. For instance, in September 2022, Thermo Fisher Scientific Inc. received FDA approval for its Oncomine Dx Target Test. This is a companion diagnostic (CDx) test for RET-fusion-positive or metastatic non-small cell lung cancer patients.
- Companies such as Danaher. (Integrated DNA Technologies, Inc.) partnered with Munich Leukaemia Laboratory (MLL)in March 2022 to join the company's align program. The extensive sequencing portfolio of MLL combined with the company's xGen portfolio of NGS solutions helped researchers with their NGS workflow needs.
Impact of COVID-19
In March 2019, the world was hit by a storm with the SARS-CoV-2 virus, which led to the shutting down of the entire world and everybody getting tested for the virus. As the amount of testing increased, it became important to increase the pace of testing as well. Research in sequencing the genome of the virus amplified, and governments provided lots of grants for the sequencing of the virus for syringe manufacturing.
The amplicon-based next-generation sequencing (NGS) method was widely used for genome sequencing. This is due to the ease of use and low sequencing cost of this method. This has made it the method of choice among many laboratories. COVID-19 genome sequencing is accomplished using a probe-based liquid phase hybridization technique, which can then be followed by NGS sequencing. The appeal of using target capture NGS methodology has the ability to enrich the limitless repertoire of genetic loci without the constant need to update primers and to deal with multiplexing issues that are encountered by amplicon-based approaches. That's another reason why virome target capture NGS methodologies are being developed. The target capture-based NGS approach has another advantage, i.e., it is better at sequencing degraded samples as compared to other NGS approaches. End-to-end target-based NGS solution, which is validated for concurrent detection and sequencing characterization for respiratory viruses like SARS-CoV-2 and other respiratory pathogens, is a powerful tool for genomic surveillance in the post-COVID-19 era and can play a crucial role in the timely generation and dissemination of the genomic data.
Market Segmentation:
Segmentation 1: by Product Type
- Instruments
- Kits/Panels and Assays
- Services
- Other Product Types
The global targeted sequencing market in product type is expected to be dominated by services segment during the forecast period 2022-2032. This is due to the increasing use of targeted sequences by small and mid-sized companies for whom opting for services is cheaper than purchasing sequencing instruments.
Segmentation 2: by Target Enrichment Method
- Hybridization Capture
- Amplicon Sequencing
- Other Target Enrichment Methods
The target enrichment method segment is expected to be dominated by the amplicon sequencing segment during the forecast period 2022-2032. This is because amplicon sequencing is an older technology and is currently more trusted, whereas hybridization capture is faster and more efficient, and thus, the segment is expected to grow at a higher CAGR in the coming years.
Segmentation 3: by Type of Target Capture
- Targeted DNA Sequencing
- Targeted RNA Sequencing
- Other Types of Target Capture
The global targeted sequencing market by type of target capture is expected to be dominated by targeted DNA sequencing segment during the forecast period 2022-2032. This is due to easy analysis and faster results when using targeted DNA sequencing segment.
Segmentation 4: by Application
- Oncology
- Reproductive Health
- Hereditary Diseases
- Neurological Disorders
- Infectious Diseases
- Cardiovascular Diseases
- Rare Diseases
- Other Applications
The oncology segment is expected to dominate the market during the forecast period 2022-2032. This growth in this segment is attributed to the increasing use of targeted sequencing in clinical applications, especially w.r.t. cancer panels.
Segmentation 5: by End User
- Diagnostic and Clinical Laboratories
- Academic and Research Institutions
- Pharmaceutical and Biotech Companies
- Other End Users
Academic and research institutions is expected to dominate the end user segment in the market during the forecast period 2022-2032. However, the diagnostic and clinical laboratories segment is supposed to grow with the fastest CAGR during the forecast period. This is due to the increasing use of targeted sequencing in clinical applications as more kits/panels, and assays get FDA approvals.
Segmentation 6: by Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Rest-of-the-World (RoW)
North America is expected to dominate the global targeted sequencing market with a revenue of $1,413.4 million in 2021. However, the Asia-Pacific (APAC) region, constituting several emerging economies, is expected to register the highest CAGR of 15.27% during the forecast period 2022-2032.
Recent Developments in Global Targeted Sequencing Market
- In August 2022, QIAGEN N.V. launched its QIAseq targeted DNA pro panels and the QIAseq UPXome RNA library kit as an expansion of its next-generation sequencing (NGS) portfolio. Both these launches lead to the growth of the company's sequencing product portfolio.
- In September 2022, BGI Group (MGI Tech Co., Ltd.) launched its DNBSEQ-G99, which is a mid to low-range throughput sequencer. This makes this sequencer especially suitable for targeted gene sequencing, small gene sequencing, and high and rapid-quality data output.
- In June 2022, Agilent Technologies, Inc. announced its collaboration with the Amazon Elastic Compute Cloud (Amazon EC2) G5g powered by Amazon Web Services (AWS) Graviton2 processors. The NVIDIA T4G Tensor Core GPUs, combined with NVIDIA Clara Parabricks' advanced genomics capabilities, improved Agilent Technologies, Inc.'s cloud-native Alissa Reporter software. This collaboration is expected to streamline the company's SureSelect family NGS assays, which comprise a wide range of custom and catalog panels.
- In June 2022, Danaher. (Integrated DNA Technologies, Inc.) made an agreement with Beckman Coulter, Inc. Life Sciences for the distribution of its Biomek NGenius Next Generation Sequencing Library Prep System. This deal helped make high-performance NGS solutions more accessible to laboratories.
Demand - Drivers and Limitations
Following are the demand drivers for the global targeted sequencing market:
- Rising Need for Sequencing at Greater Depth
- Lower Cost and Data Burden of Targeted Sequencing When Compared to Whole Genome Sequencing
- Increase in Cancer Prevalence
The market is expected to face some limitations too due to the following challenges:
- Lack of Knowledge About New Genes and Biomarkers
- Lack of High Complexity Genomic Testing Centers in High Potential Markets
How can this report add value to an organization?
- Product/Innovation Strategy: The report considers both products and services-based companies. The industry is seeing constant development and product launches with new and innovative upgrades. Additionally, new discoveries of specific biomarkers related to various diseases are increasing researchers' trust in targeted sequencing.
- Growth/Marketing Strategy: The key components in targeted sequencing are the target capture methods and various disease panels. The advancements in target capture methods like hybridization capture are reducing the cost and increasing the efficiency of this technique. Additionally, the discovery of biomarkers and other genes for various diseases is helping panel manufacturers curate precise kits and assays for targeted sequencing of specific disease types.
- Competitive Strategy: The key players in the global targeted sequencing market have been analyzed and profiled in the study, consisting of both product-based and service-based companies, as well as a few emerging companies. Moreover, a detailed competitive benchmarking of the players operating in the global targeted sequencing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts, analyzing company coverage, product portfolio, and market penetration.
The top segment players leading the market include targeted sequencing instruments, kits/panels and assays, services, and other product types providers. Targeted sequencing instrument providers constitute around 10.20% of the presence in the market, kits/panels and assays constitute 24.81% of the market, services providers constitute about 58.53% of the market, and other product types constitute 6.47% of the targeted sequencing market.
Key Companies Profiled:
|
|
Product Code: BHP1316SA
Table of Contents
1 Markets
- 1.1 Inclusion and Exclusion Criteria
- 1.2 Market Scope
- 1.2.1 Scope of the Study
- 1.2.2 Key Questions Answered in the Report
- 1.3 Research Methodology
- 1.3.1 Global Targeted Sequencing Market: Research Methodology
- 1.3.2 Data Sources
- 1.3.2.1 Primary Data Sources
- 1.3.2.2 Secondary Data Sources
- 1.3.3 Market Estimation Model
- 1.3.4 Criteria for Company Profiling
2 Market Overview
- 2.1 Market Overview
- 2.1.1 Market Definition
- 2.1.2 Market Footprint and Growth Potential
- 2.1.3 Future Potential
- 2.1.4 Comparison of Whole Genome Sequencing, Whole Exome Sequencing, and Targeted Sequencing Methods
- 2.1.5 Evolution of Targeted Sequencing (Sanger Sequencing vs. NGS)
- 2.1.5.1 First-Generation Sequencing
- 2.1.5.2 Second-Generation Sequencing (Next-Generation Sequencing)
- 2.1.5.3 Third-Generation Sequencing
- 2.1.6 COVID-19 Impact on Targeted Sequencing Market
- 2.1.6.1 Impact on Research and Clinical Operations
- 2.1.6.2 COVID-19 Impact: Current Scenario of the Market
3 Industry Analysis
- 3.1 Legal Requirements
- 3.1.1 Legal Requirements and Framework in the U.S.
- 3.1.2 U.S. FDA Published Guidance
- 3.1.3 U.S. FDA Regulations
- 3.1.4 Legal Requirements Framework in Europe
- 3.1.5 Legal Requirements and Framework in Asia-Pacific
- 3.1.5.1 China
- 3.1.5.2 Japan
- 3.1.5.2.1 Pharmaceuticals and Medical Devices Agency (PMDA)
- 3.1.5.2.2 Ministry of Health, Labour and Welfare (MHLW)
- 3.1.5.3 India
- 3.2 Patent Analysis
- 3.2.1 Patent Filing Trend
- 3.2.2 Patent Analysis (by Year)
- 3.2.3 Patent Analysis (by Country)
- 3.2.4 Patent Analysis (by Region)
4 Market Dynamics
- 4.1 Overview
- 4.2 Impact Analysis
- 4.3 Market Drivers
- 4.3.1 Rising Need for Sequencing at Greater Depth
- 4.3.2 Lower Cost and Data Burden of Targeted Sequencing When Compared to Whole Genome Sequencing
- 4.3.3 Increase in Cancer Prevalence
- 4.4 Market Challenges
- 4.4.1 Lack of Knowledge About New Genes and Biomarkers
- 4.4.2 Lack of High Complexity Genomic Testing Centers in High Potential Markets
- 4.5 Market Opportunities
- 4.5.1 Increasing Use in Clinical Research and Trials for Better Disease Pathogenesis and/or Clinical Relevance
- 4.5.2 Rising Adoption of Targeted Sequencing in Targeted Therapeutics
5 Competitive Landscape
- 5.1 Overview
- 5.2 Corporate Strategies
- 5.2.1 Mergers and Acquisitions
- 5.2.2 Synergistic Activities
- 5.3 Business Strategies
- 5.3.1 Product Launches/Upgradations
- 5.3.2 Business Expansion and Funding
- 5.4 Supply Chain Analysis
- 5.4.1 Key Entities in Supply Chain
- 5.5 Market Share Analysis (by Company)
- 5.6 Growth Share Analysis
- 5.6.1 Growth Share Analysis (by Application)
- 5.6.2 Growth Share Analysis (by End User)
6 Global Targeted Sequencing Market (by Product Type), ($Million), 2021-2032
- 6.1 Overview
- 6.2 Services
- 6.3 Kits/Panels and Assays
- 6.4 Instruments
- 6.5 Other Product Types
7 Global Targeted Sequencing Market (By Target Enrichment Method), ($Million), 2021-2032
- 7.1 Overview
- 7.2 Amplicon Sequencing
- 7.3 Hybridization Capture
- 7.4 Other Target Enrichment Methods
8 Global Targeted Sequencing Market (by Type of Target Capture), $Million, 2021-2032
- 8.1 Overview
- 8.2 Targeted DNA Sequencing
- 8.2.1 Targeted Methyl Sequencing
- 8.3 Targeted RNA Sequencing
- 8.3.1 Targeted Metagenomic Sequencing
- 8.4 Other Types of Target Capture
9 Global Targeted Sequencing Markets (by Application), $Million, 2021-2032
- 9.1 Overview
- 9.2 Oncology
- 9.2.1 Solid Tumor
- 9.2.2 Liquid Biopsy
- 9.2.3 Minimal Residual Disease Testing
- 9.2.4 Circulating Tumor Cell (CTC) Analysis
- 9.3 Infectious Diseases
- 9.4 Cardiovascular Diseases
- 9.5 Reproductive Health
- 9.5.1 Carrier Screening
- 9.5.2 Non-Invasive Prenatal Testing
- 9.5.3 Preimplantation Genetic Diagnosis (PGD)
- 9.5.4 Newborn Screening
- 9.6 Rare Diseases
- 9.7 Neurological Disorders
- 9.8 Hereditary Diseases
- 9.9 Other Applications
10 Global Targeted Sequencing Market (By End User), ($Million), 2021-2032
- 10.1 Overview
- 10.1.1 Academic and Research Institutions
- 10.1.2 Pharmaceutical and Biotech Companies
- 10.1.3 Diagnostic and Clinical Laboratories
- 10.1.4 Other End Users
11 Global Targeted Sequencing Market, by Region, $Million, 2021-2032
- 11.1 Overview
- 11.2 North America
- 11.2.1 U.S.
- 11.2.2 Canada
- 11.3 Europe
- 11.3.1 Germany
- 11.3.2 France
- 11.3.3 U.K.
- 11.3.4 Italy
- 11.3.5 Spain
- 11.3.6 Rest-of-Europe
- 11.4 Asia-Pacific
- 11.4.1 China
- 11.4.2 Japan
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 South Korea
- 11.4.6 Rest-of-Asia-Pacific
- 11.5 Latin America
- 11.5.1 Brazil
- 11.5.2 Mexico
- 11.5.3 Rest-of-Latin America
- 11.6 Rest-of-the-World (RoW)
12 Company Profiles
- 12.1 Overview
- 12.2 Market Value Chain of Targeted Sequencing Market
- 12.3 Agilent Technologies, Inc.
- 12.3.1 Company Overview
- 12.3.2 Role of Agilent Technologies, Inc. in the Global Targeted Sequencing Market
- 12.3.3 Key Customers of the Company
- 12.3.4 Key Competitors of the Company
- 12.3.5 Financials
- 12.3.6 Key Insights about the Financial Health of the Company
- 12.3.7 Corporate Strategies
- 12.3.7.1 Synergistic Activities
- 12.3.8 Business Strategies
- 12.3.8.1 Business Expansion and Funding
- 12.3.9 Analyst Perspective
- 12.4 Azenta US, Inc. (GENEWIZ)
- 12.4.1 Company Overview
- 12.4.2 Role of Azenta US, Inc. in the Global Targeted Sequencing Market
- 12.4.3 Key Customers of the Company
- 12.4.4 Key Competitors of the Company
- 12.4.5 Financials
- 12.4.6 Key Insights about the Financial Health of the Company
- 12.4.7 Corporate Strategies
- 12.4.7.1 Synergistic Activities
- 12.4.8 Business Strategies
- 12.4.8.1 Business Expansion and Funding
- 12.4.9 Analyst Perspective
- 12.5 BGI Group (MGI Tech Co., Ltd.)
- 12.5.1 Company Overview
- 12.5.2 Role of BGI Group in the Global Targeted Sequencing Market
- 12.5.3 Key Competitors of the Company
- 12.5.4 Business Strategies
- 12.5.5 Analyst Perspective
- 12.6 CD Genomics
- 12.6.1 Company Overview
- 12.6.2 Role of CD Genomics in the Global Targeted Sequencing Market
- 12.6.3 Key Competitors of the Company
- 12.6.4 Business Strategies
- 12.6.4.1 Product Launches and Upgradations
- 12.6.5 Analyst Perspective
- 12.7 Daicel Corporation (Daicel Arbor Biosciences)
- 12.7.1 Company Overview
- 12.7.2 Role of Daicel Corporation (Daicel Arbor Biosciences) in the Global Targeted Sequencing Market
- 12.7.3 Key Customers of the Company
- 12.7.4 Key Competitors of the Company
- 12.7.5 Financials
- 12.7.6 Key Insights about the Financial Health of the Company
- 12.7.7 Corporate Strategies
- 12.7.7.1 Mergers and Acquisitions
- 12.7.7.2 Synergistic Activities
- 12.7.8 Analyst Perspective
- 12.8 Danaher. (Integrated DNA Technologies, Inc.)
- 12.8.1 Company Overview
- 12.8.2 Role of Danaher. in the Global Targeted Sequencing Market
- 12.8.3 Key Customers of the Company
- 12.8.4 Key Competitors of the Company
- 12.8.5 Financials
- 12.8.6 Key Insights about the Financial Health of the Company
- 12.8.7 Corporate Strategies
- 12.8.7.1 Mergers and Acquisitions
- 12.8.7.2 Synergistic Activities
- 12.8.8 Business Strategies
- 12.8.8.1 Product Launch/ Approval
- 12.8.8.2 Funding and Expansion
- 12.8.9 Analyst Perspective
- 12.9 F. Hoffmann-La Roche Ltd
- 12.9.1 Company Overview
- 12.9.2 Role of F. Hoffmann-La Roche Ltd in the Global Targeted Sequencing Market
- 12.9.3 Key Competitors of the Company
- 12.9.4 Financials
- 12.9.5 Key Insights about the Financial Health of the Company
- 12.9.6 Corporate Strategies
- 12.9.6.1 Mergers and Acquisitions
- 12.9.6.2 Synergistic Activities
- 12.9.7 Business Strategies
- 12.9.7.1 Product Launches and Upgradations
- 12.9.8 Analyst Perspective
- 12.1 Illumina, Inc.
- 12.10.1 Company Overview
- 12.10.2 Role of Illumina, Inc. in the Global Targeted Sequencing Market
- 12.10.3 Key Competitors of the Company
- 12.10.4 Financials
- 12.10.5 Key Insights about the Financial Health of the Company
- 12.10.6 Corporate Strategies
- 12.10.6.1 Synergistic Activities
- 12.10.7 Business Strategies
- 12.10.7.1 Product Launches and Upgradations
- 12.10.7.2 Funding and Expansion
- 12.10.8 Analyst Perspective
- 12.11 LGC Limited (LGC Biosearch Technologies)
- 12.11.1 Company Overview
- 12.11.2 Role of LGC Limited (LGC Biosearch Technologies) in the Global Targeted Sequencing Market
- 12.11.3 Key Competitors of the Company
- 12.11.4 Financials
- 12.11.5 Key Insights about the Financial Health of the Company
- 12.11.6 Corporate Strategies
- 12.11.6.1 Mergers and Acquisitions
- 12.11.6.2 Synergistic Activities
- 12.11.7 Analyst Perspective
- 12.12 PacBio.
- 12.12.1 Company Overview
- 12.12.2 Role of PacBio. in the Global Targeted Sequencing Market
- 12.12.3 Key Customers of the Company
- 12.12.4 Key Competitors of the Company
- 12.12.5 Financials
- 12.12.6 Key Insights about the Financial Health of the Company
- 12.12.7 Corporate Strategies
- 12.12.7.1 Mergers and Acquisitions
- 12.12.7.2 Synergistic Activities
- 12.12.8 Business Strategies
- 12.12.8.1 Product Launches and Upgradations
- 12.12.9 Analyst Perspective
- 12.13 PerkinElmer Inc.
- 12.13.1 Company Overview
- 12.13.2 Role of PerkinElmer Inc. in the Global Targeted Sequencing Market
- 12.13.3 Key Customers of the Company
- 12.13.4 Key Competitors of the Company
- 12.13.5 Financials
- 12.13.6 Key Insights about the Financial Health of the Company
- 12.13.7 Corporate Strategies
- 12.13.7.1 Synergistic Activities
- 12.13.8 Business Strategies
- 12.13.8.1 Product Launches and Upgradations
- 12.13.9 Analyst Perspective
- 12.14 Psomagen
- 12.14.1 Company Overview
- 12.14.2 Role of Psomagen in the Global Targeted Sequencing Market
- 12.14.3 Key Customers of the Company
- 12.14.4 Key Competitors of the Company
- 12.14.5 Financials
- 12.14.6 Corporate Strategies
- 12.14.6.1 Synergistic Activities
- 12.14.7 Analyst Perspective
- 12.15 QIAGEN N.V.
- 12.15.1 Company Overview
- 12.15.2 Role of QIAGEN N.V. in the Global Targeted Sequencing Market
- 12.15.3 Key Customers of the Company
- 12.15.4 Key Competitors of the Company
- 12.15.5 Financials
- 12.15.6 Key Insights about the Financial Health of the Company
- 12.15.7 Corporate Strategies
- 12.15.7.1 Synergistic Activities
- 12.15.8 Business Strategies
- 12.15.8.1 Product Launches and Upgradations
- 12.15.9 Analyst Perspective
- 12.16 Takara Bio Inc.
- 12.16.1 Company Overview
- 12.16.2 Role of Takara Bio Inc. in the Global Targeted Sequencing Market
- 12.16.3 Key Customers of the Company
- 12.16.4 Key Competitors of the Company
- 12.16.5 Financials
- 12.16.6 Key Insights about the Financial Health of the Company
- 12.16.7 Analyst Perspective
- 12.17 Tecan Trading AG
- 12.17.1 Company Overview
- 12.17.2 Role of Tecan Trading AG in the Global Targeted Sequencing Market
- 12.17.3 Key Customers of the Company
- 12.17.4 Key Competitors of the Company
- 12.17.5 Financials
- 12.17.6 Key Insights about the Financial Health of the Company
- 12.17.7 Corporate Strategies
- 12.17.7.1 Synergistic Activities
- 12.17.8 Business Strategies
- 12.17.8.1 Product Launches and Upgradations
- 12.17.9 Analyst Perspective
- 12.18 Thermo Fisher Scientific Inc.
- 12.18.1 Company Overview
- 12.18.2 Role of Thermo Fisher Scientific Inc. in the Global Targeted Sequencing Market
- 12.18.3 Key Customers of the Company
- 12.18.4 Key Competitors of the Company
- 12.18.5 Financials
- 12.18.6 Key Insights about the Financial Health of the Company
- 12.18.7 Corporate Strategies
- 12.18.7.1 Synergistic Activities
- 12.18.8 Corporate Strategies
- 12.18.8.1 Synergistic Activities
- 12.18.9 Business Strategies
- 12.18.9.1 Product Launches and Upgradations
- 12.18.9.2 Funding and Expansion
- 12.18.10 Analyst Perspective
- 12.19 Twist Bioscience.
- 12.19.1 Company Overview
- 12.19.2 Role of Twist Bioscience. in the Global Targeted Sequencing Market
- 12.19.3 Key Customers of the Company
- 12.19.4 Key Competitors of the Company
- 12.19.5 Financials
- 12.19.6 Key Insights about the Financial Health of the Company
- 12.19.7 Corporate Strategies
- 12.19.7.1 Synergistic Activities
- 12.19.8 Business Strategies
- 12.19.8.1 Product Launches and Upgradations
- 12.19.9 Analyst Perspective
- 12.2 Emerging Companies
- 12.20.1 MedGenome
- 12.20.2 Novogene Co, Ltd.
- 12.20.3 Paragon Genomics, Inc.
- 12.20.4 Sage Science, Inc.
- 12.20.5 Zymo Research Corporation.
Product Code: BHP1316SA
List of Figures
- Figure 1: Global Targeted Sequencing Market, $Million, 2021 and 2032
- Figure 2: Global Targeted Sequencing Market Segmentation
- Figure 3: Global Targeted Sequencing Market (by Product Type), $Million, 2021-2032
- Figure 4: Global Targeted Sequencing Market (by Target Enrichment Method), $Million, 2021-2032
- Figure 5: Global Targeted Sequencing Market (by Type of Target Capture), $Million, 2021-2032
- Figure 6: Global Targeted Sequencing Market (by Application), $Million, 2021-2032
- Figure 7: Global Targeted Sequencing Market (by End User), $Million, 2021-2032
- Figure 8: Global Targeted Sequencing Market (by Region)
- Figure 9: Global Targeted Sequencing Market Segmentation
- Figure 10: Global Targeted Sequencing Market: Research Methodology
- Figure 11: Primary Research Methodology
- Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 13: Top-Down Approach (Segment-Wise Analysis)
- Figure 14: Comparison between Whole Genome Sequencing, Whole Exome Sequencing, and Targeted Sequencing Methods
- Figure 15: Whole Genome Sequencing
- Figure 16: Whole Exome Sequencing
- Figure 17: Targeted Sequencing
- Figure 18: Evolution of Targeted Sequencing Over the Three Generations
- Figure 19: FDA's Regulatory Insight System
- Figure 20: Global Targeted Sequencing Market, Patent Analysis (by Year), January 2020-December 2022
- Figure 21: Global Targeted Sequencing Market, Patent Analysis (by Country), January 2020-December 2022
- Figure 22: Global Targeted Sequencing Market, Patent Analysis (by Region), January 2020-December 2022
- Figure 23: Global Targeted Sequencing Market Dynamics
- Figure 24: Global Cancer Deaths between 2010-2019
- Figure 25: Share of Key Developments, January 2020-December 2022
- Figure 26: Share of Mergers and Acquisitions (by Company), January 2019-December 2022
- Figure 27: Share of Synergistic Activities (by Company), January 2019-December 2022
- Figure 28: Share of Product Launches/Upgradations (by Company), January 2019-December 2022
- Figure 29: Share of Business Expansion and Funding Activities (by Company), January 2019-December 2022
- Figure 30: Targeted Sequencing Supply Chain Analysis
- Figure 31: Market Share Analysis of Global Targeted Sequencing Market (by Company), 2021
- Figure 32: Growth Share Analysis for Global Targeted Sequencing Market (by Application), 2021
- Figure 33: Growth Share Analysis for Global Targeted Sequencing Market (by End User), 2021
- Figure 34: Evolution of Biological Foundations' Dominance over Time
- Figure 35: Global Targeted Sequencing Market (by Product Type)
- Figure 36: Global Targeted Sequencing Market (by Product Type), $Million, 2021 and 2032
- Figure 37: Sequencing Services Workflow
- Figure 38: Global Targeted Sequencing Market (Services), $Million, 2021-2032
- Figure 39: Global Targeted Sequencing Market (Kits/Panels and Assays), $Million, 2021-2032
- Figure 40: Global Targeted Sequencing Market (Instruments), $Million, 2021-2032
- Figure 41: Global Targeted Sequencing Market (Other Product Types), $Million, 2021-2032
- Figure 42: Global Targeted Sequencing Market (by Target Enrichment Method)
- Figure 43: Global Targeted Sequencing Market (by Target Enrichment Method), $Million, 2021 and 2032
- Figure 44: Workflow of Amplicon Sequencing
- Figure 45: Global Targeted Sequencing Market (Amplicon Sequencing), $Million, 2021-2032
- Figure 46: Hybridization Capture Workflow
- Figure 47: Global Targeted Sequencing Market (Hybridization Capture), $Million, 2021-2032
- Figure 48: Global Targeted Sequencing Market (Other Target Enrichment Methods), $Million, 2021-2032
- Figure 49: Global Targeted Sequencing Market (by Type of Target Capture)
- Figure 50: Global Targeted Sequencing Market (by Type of Target Capture), $Million, 2021 and 2032
- Figure 51: Global Targeted Sequencing Market (Targeted DNA Sequencing), $Million, 2021-2032
- Figure 52: Targeted Methyl Sequencing Workflow
- Figure 53: Targeted RNA Sequencing Workflow
- Figure 54: Global Targeted Sequencing Market (Targeted RNA Sequencing), $Million, 2021-2032
- Figure 55: Global Targeted Sequencing Market (Other Types of Target Capture), $Million, 2021-2032
- Figure 56: Global Targeted Sequencing Market (by Application)
- Figure 57: Global Targeted Sequencing Market (by Application), $Million, 2021 and 2032
- Figure 58: Global Targeted Sequencing Market (Oncology), $Million, 2021-2032
- Figure 59: Global Targeted Sequencing Market (Infectious Diseases), $Million, 2021-2032
- Figure 60: Global Targeted Sequencing Market (Cardiovascular Diseases), $Million, 2021-2032
- Figure 61: Global Targeted Sequencing Market (Reproductive Health), $Million, 2021-2032
- Figure 62: Global Targeted Sequencing Market (Rare Diseases), $Million, 2021-2032
- Figure 63: Global Targeted Sequencing Market (Neurological Disorders), $Million, 2021-2032
- Figure 64: Global Targeted Sequencing Market (Hereditary Diseases), $Million, 2021-2032
- Figure 65: Global Targeted Sequencing Market (Other Applications), $Million, 2021-2032
- Figure 66: Global Targeted Sequencing Market (by End User)
- Figure 67: Global Targeted Sequencing Market (by End User), $Million, 2021-2032
- Figure 68: Global Targeted Sequencing Market (Academic and Research Institutes), $Million, 2021-2032
- Figure 69: Global Targeted Sequencing Market (Pharmaceutical and Biotech Companies), $Million, 2021-2032
- Figure 70: Global Targeted Sequencing Market (Diagnostic and Clinical Laboratories), $Million, 2021-2032
- Figure 71: Global Targeted Sequencing Market (Other End Users), $Million, 2021-2032
- Figure 72: Global Targeted Sequencing Market (by Region)
- Figure 73: Global Targeted Sequencing Market (by Region), $Million, 2021-2032
- Figure 74: North America Targeted Sequencing Market, $Million, 2021-2032
- Figure 75: North America: M-arket Dynamics
- Figure 76: North America Targeted Sequencing Market (by Country), $Million, 2021-2032
- Figure 77: U.S. Targeted Sequencing Market, $Million, 2021-2032
- Figure 78: Canada Targeted Sequencing Market, $Million, 2021-2032
- Figure 79: Europe Targeted Sequencing Market, $Million, 2021-2032
- Figure 80: Europe: Market Dynamics
- Figure 81: Europe Targeted Sequencing Market (by Country), $Million, 2021-2032
- Figure 82: Germany Targeted Sequencing Market, $Million, 2021-2032
- Figure 83: France Targeted Sequencing Market, $Million, 2021-2032
- Figure 84: U.K. Targeted Sequencing Market, $Million, 2021-2032
- Figure 85: Italy Targeted Sequencing Market, $Million, 2021-2032
- Figure 86: Spain Targeted Sequencing Market, $Million, 2021-2032
- Figure 87: Rest-of-Europe Targeted Sequencing Market, $Million, 2021-2032
- Figure 88: Asia-Pacific Targeted Sequencing Market, $Million, 2021-2032
- Figure 89: Asia-Pacific - Market Dynamics
- Figure 90: Asia-Pacific Targeted Sequencing Market (by Country), $Million, 2021-2032
- Figure 91: China Targeted Sequencing Market, $Million, 2021-2032
- Figure 92: Japan Targeted Sequencing Market, $Million, 2021-2032
- Figure 93: India Targeted Sequencing Market, $Million, 2021-2032
- Figure 94: Australia Targeted Sequencing Market, $Million, 2021-2032
- Figure 95: South Korea Targeted Sequencing Market, $Million, 2021-2032
- Figure 96: Rest-of-Asia-Pacific Targeted Sequencing Market, $Million, 2021-2032
- Figure 97: Latin America Targeted Sequencing Market, $Million, 2021-2032
- Figure 98: Latin America - Market Dynamics
- Figure 99: Latin America Targeted Sequencing Market (by Country), $Million, 2021-2032
- Figure 100: Brazil Targeted Sequencing Market, $Million, 2021-2032
- Figure 101: Mexico Targeted Sequencing Market, $Million, 2021-2032
- Figure 102: Rest-of-Latin America Targeted Sequencing Market, $Million, 2021-2032
- Figure 103: Rest-of-the-World Targeted Sequencing Market, $Million, 2021-2032
- Figure 104: Total Number of Companies Profiled
- Figure 105: Global Targeted Sequencing Market: Value Chain
- Figure 106: Agilent Technologies, Inc.: Product Portfolio
- Figure 107: Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021
- Figure 108: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 109: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 110: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 111: Azenta US, Inc.: Product Portfolio
- Figure 112: Azenta US, Inc.: Overall Financials, $Million, 2019-2021
- Figure 113: Azenta US, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 114: Azenta US, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 115: Azenta US, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 116: BGI Group: Product Portfolio
- Figure 117: CD Genomics: Product Portfolio
- Figure 118: Daicel Corporation: Product Portfolio
- Figure 119: Daicel Corporation: Overall Financials, $Million, 2020-2022
- Figure 120: Daicel Corporation: Revenue (by Segment), $Million, 2020-2022
- Figure 121: Daicel Corporation: Revenue (by Region), $Million, 2020-2022
- Figure 122: Daicel Corporation: R&D Expenditure, $Million, 2020-2022
- Figure 123: Danaher.: Product Portfolio
- Figure 124: Danaher.: Overall Financials, $Million, 2019-2021
- Figure 125: Danaher.: Revenue (by Segment), $Million, 2019-2021
- Figure 126: Danaher.: Revenue (by Region), $Million, 2019-2021
- Figure 127: Danaher.: R&D Expenditure, $Million, 2019-2021
- Figure 128: F. Hoffmann-La Roche Ltd: Product Portfolio
- Figure 129: F. Hoffmann-La Roche Ltd: Overall Financials, 2019-2021
- Figure 130: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2019-2021
- Figure 131: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2019-2021
- Figure 132: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2019-2021
- Figure 133: Illumina, Inc.: Product Portfolio
- Figure 134: Illumina, Inc.: Overall Financials, $Million, 2019-2021
- Figure 135: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 136: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 137: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 138: LGC Limited: Product Portfolio
- Figure 139: LGC Limited: Overall Financials, $Million, 2020-2022
- Figure 140: LGC Limited: Revenue (by Segment), $Million, 2020-2022
- Figure 141: LGC Group: R&D Expenditure, $Million, 2020-2022
- Figure 142: PacBio.: Product Portfolio
- Figure 143: PacBio.: Overall Financials, $Million, 2019-2021
- Figure 144: PacBio.: Revenue (by Segment), $Million, 2019-2021
- Figure 145: PacBio.: Revenue (by Region), $Million, 2019-2021
- Figure 146: PacBio.: R&D Expenditure, $Million, 2019-2021
- Figure 147: PerkinElmer Inc.: Product Portfolio
- Figure 148: PerkinElmer Inc.: Overall Financials, $Million, 2019-2021
- Figure 149: PerkinElmer Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 150: PerkinElmer Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 151: PerkinElmer Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 152: Psomagen: Product Portfolio
- Figure 153: Psomagen: Overall Financials, $Million, 2019-2021
- Figure 154: QIAGEN N.V.: Product Portfolio
- Figure 155: QIAGEN N.V.: Overall Financials, $Million, 2019-2021
- Figure 156: QIAGEN N.V.: Revenue (by Segment), $Million, 2019-2021
- Figure 157: QIAGEN N.V.: Revenue (by Region), $Million, 2019-2021
- Figure 158: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
- Figure 159: Takara Bio Inc.: Product Portfolio
- Figure 160: Takara Bio Inc.: Overall Financials, $Million, 2019-2021
- Figure 161: Takara Bio Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 162: Takara Bio Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 163: Takara Bio Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 164: Tecan Trading AG: Product Portfolio
- Figure 165: Tecan Trading AG: Overall Financials, $Million, 2019-2021
- Figure 166: Tecan Trading AG: Revenue (by Segment), $Million, 2019-2021
- Figure 167: Tecan Trading AG: Revenue (by Region), $Million, 2019-2021
- Figure 168: Tecan Trading AG: R&D Expenditure, $Million, 2019-2021
- Figure 169: Thermo Fisher Scientific Inc.: Product Portfolio
- Figure 170: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
- Figure 171: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 172: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 173: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 174: Twist Bioscience.: Product Portfolio
- Figure 175: Twist Bioscience.: Overall Financials, $Million, 2020-2022
- Figure 176: Twist Bioscience.: Revenue (by Segment), $Million, 2020-2022
- Figure 177: Twist Bioscience.: Revenue (by Region), $Million, 2020-2022
- Figure 178: Twist Biosciences.: R&D Expenditure, $Million, 2020-2022
List of Tables
- Table 1: Likert Scale
- Table 2: Impact Analysis of Market Drivers, Restraints, and Opportunities on the Global Targeted Sequencing Market
- Table 3: Technological Trends in Targeted Sequencing Market
- Table 4: Likert Scale
- Table 5: Impact Analysis of Market Drivers
- Table 6: Impact Analysis of Market Restraints
- Table 7: Impact Analysis of Market Opportunities
- Table 8: Comparison Between Types of Next-Generation Sequencing Techniques (Comparison)
- Table 9: Comparing Targeted Sequencing Methods
- Table 10: Advantages and Disadvantages of Liquid Biopsy
- Table 11: Whole Genome and Targeted Sequencing Methods using NIPT Data
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.